[Limitations in application of imatinib in hematologic malignancies: are there new principal solutions?]

Ter Arkh. 2008;80(7):80-4.
[Article in Russian]
No abstract available

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Benzamides
  • Hematologic Neoplasms / drug therapy*
  • Humans
  • Imatinib Mesylate
  • Piperazines / therapeutic use*
  • Practice Guidelines as Topic*
  • Protein-Tyrosine Kinases / antagonists & inhibitors
  • Pyrimidines / therapeutic use*
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate
  • Protein-Tyrosine Kinases